ALVO
Alvotech

192
Loading...
Loading...
News
all
press releases
Voyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock?
Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·6d ago
News Placeholder
More News
News Placeholder
Here's How Alvotech is Expanding its Portfolio Beyond Immunology
ALVO accelerates growth with soaring revenues and new biosimilars in ophthalmology, oncology and neurology via global alliances.
Zacks·15d ago
News Placeholder
Alvotech (ALVO) Surges 8.6%: Is This an Indication of Further Gains?
Alvotech (ALVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·21d ago
News Placeholder
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.
Zacks·22d ago
News Placeholder
Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth
Alvotech's partnership-led strategy drives soaring biosimilar revenues, fresh approvals and a diversified pipeline across key therapies.
Zacks·27d ago
News Placeholder
ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
Alvotech trades near a 52-week low after a 38% drop in 2025, but soaring revenues and new biosimilar approvals highlight its growth path.
Zacks·1mo ago
News Placeholder
Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus
KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.
Zacks·2mo ago
News Placeholder
Alvotech (ALVO) Q2 Earnings and Revenues Beat Estimates
Alvotech (ALVO) delivered earnings and revenue surprises of +153.85% and +50.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Wall Street Analysts Think Alvotech (ALVO) Could Surge 102.31%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 102.3% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·2mo ago
News Placeholder
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -38.89% and +0.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago

Latest ALVO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.